Перегляд за автором "Rivkina, A."

Результати 1-3 з 3

Generic imatinib in the treatment of chronic myeloid leukemia: two years’ experience in latvia

Lejniece, S.; Udre, I.; Rivkina, A. (Experimental Oncology, 2017)

Background: Imatinib is tyrosine kinase inhibitor (TKI) and as a targeted anti-cancer agent has significantly changed chronic myeloid leukemia (CML) prognosis and patient survival. Currently TKI is the main therapy in CML ...
Identifying the stage of new CLL patients using TK, ZAP-70, CD38 levels

Rivkina, A.; Vitols, G.; Murovska, M.; Lejniece, S. (Experimental Oncology, 2011)

Serum thymidine kinase (TK), zeta-associated protein of 70 kDa (ZAP-70) and CD38 levels have been shown to be correlated with survival in chronic lymphocytic leukaemia (CLL). Aim: To investigate the possible correlations ...
Peripheral blood lymphocyte phenotype of ZAP-70⁺ and ZAP-70⁻ patients with B-cell chronic lymphocytic leukaemia

Rivkina, A.; Kholodyuk I. Holodnuka; Murovska, M.; Soloveichika, M.; Lejniece, S. (Experimental Oncology, 2015)

Background: Up to now, the immune status of chronic lymphocytic leukemia (CLL) patients in association with the expression of zeta-chain-associated protein kinase 70 (ZAP-70) in leukemic cells has not been evaluated. Aim: ...

Результати 1-3 з 3

Пошук